Clinical Trial

Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients

Study acronym: Neuro-KTR
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The objective of this randomized controlled study is to assess the neurocognitive outcomes between individuals using immediate-release (IR) tacrolimus (Prograf®) and those who were converted to extended-release tacrolimus (Envarsus XR) among older kidney transplant recipients (KTRs).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-12-20; most recent amendment 2026-05-26.
Status change: Not Yet Recruiting → Recruiting 2026-03-17
Trial Details
NCT Number NCT06751992
Lead Sponsor Massachusetts General Hospital
Collaborators: Veloxis Pharmaceuticals
Conditions Kidney Transplant Recipients, Old Age
Enrollment 92 participants
Start Date 2026-03-17
Primary Completion 2027-05-01 (estimated)
Study Completion 2027-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-28